RECRUITING STUDIES

Bevirimat: A New Investigational HIV Maturation Inhibitor

This study, which lasts only 21 days, will look at the dose, viral load effects, and side effects of an investigational drug called bevirimat, made by Panacos Pharmaceuticals. This is the first drug in a new class called maturation inhibitors. This drug causes HIV-infected T-cells to produce immature HIV that cannot infect new cells. We will study several doses of bevirimat or placebo given once a day for 14 days on top of a failing regimen to see if the drug will be safe, well-tolerated, and effective in lowering viral load. All study-related labs and procedures are free.

  • Currently on anti-HIV meds for at least 8 weeks
  • Viral load 2,000 - 250,000 copies
  • CD4+ T-cells over 100 cells/ µL
  • Reimbursement up to $2100

And Now For Something Entirely New...Viral Decay Acceleration

One of our newest studies involves an investigational drug from Koronis called KP1461. This drug is the first of a new class called viral decay accelerators. This drug causes HIV to make random errors when it reproduces, ultimately killing the virus or making it unable to infect cells. Participants in this study will take KP-1461 alone for 124 days. We will study safety, tolerability, and changes in viral load and CD4 counts.

  • Koronis KP1461 Study: Resistance to at least one drug in each of 3 classes of anti-HIV drugs but not currently on drugs
  • Viral load over 2,500 copies/ml; CD4+ T-cells over 250 cells/µL
  • Study reimbursement up to $2000

MK-0518 (Merck Integrase Inhibitor) vs Kaletra® Switch Study

Is your viral load "undetectable" on Kaletra® and other drugs? You might be eligible to participate in this study in which you would stay on Kaletra® or change to the new Merck integrase inhibitor, MK-0518. We will study your viral load and CD4+ T-cell counts as well as cholesterol and other lipids, blood sugar, and other safety labs. All labs and Kaletra® or raltegravir are free of charge.

  • Viral load less than 50 copies/ml on a Kaletra-containing regimen
  • Not on lipid-lowering medicines in the last 12 weeks

Acute and Recent HIV Infection: Does Short Term Treatment Help Control the Virus?

No one knows whether we should treat someone who is newly infected with HIV with anti-HIV drugs. This study, sponsored by the National Institutes of Health and the University of Colorado will try to shed some light on that question. To be eligible, you must have been infected (not just diagnosed) with HIV within the last six months. Participants will be randomized (assigned by chance) to taking Kaletra and Truvada for 12 weeks or not taking drugs. If, at the end of 12 weeks, your T-cell count is high enough, you will discontinue drugs. If at any time your T-cell count drops below 250 cells/µl in either arm of the study, you will be given the opportunity to go on the study drugs free of charge.

  • Newly infected with HIV within 6 months
  • Never on HIV meds more than one week

HIV Testing Study: Only One Visit!

We are working with CDC to look at the accuracy of different kinds of HIV tests. This study involves only one visit, a fingerstick, an oral swab, and a blood draw. You must not be on any anti-HIV drugs. Reimbursement is $20 for the visit.

  • HIV+ but not on anti- HIV meds
  • Reimbursement $20 for the visit

New CCR5 Antibody Study Coming Soon!

December for a study of an antibody that blocks the CCR5 receptor on T-cells to keep HIV from entering the cell. In the first study of this drug, done last year, we found a strong effect against the virus after only one IV dose of the drug. This study will study two different dose levels of study drug with follow-up for 59 days. There are frequent visits during the first 2 weeks. Only one IV dose of study drug or placebo is given.

  • Not on anti-HIV drugs for last 12 weeks
  • Viral load over 1000 copies and CD4+ over 250 cells
  • Reimbursement $1000

Risks, benefits, and additional study requirements will be discussed with you before you join a study.

Please call for information on enrolling studies.

Back to home